drugset / Trial / NCT07368959

AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

NCT07368959 ↗

Phase 3 Recruiting 120 enrolled Aurion Biotech
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of single injection dose of AURN001 compared with placebo in adult participants with corneal edema secondary to corneal endothelial dysfunction.

Timeline

Start
2026-02-19
Primary completion
2027-06
Completion
2028-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AURN001 Unknown — Other
Subject Y27632 Small molecule — Other